Live tape
Top 8, mentions 7d10,784GOOGL2,064 mentions▲ +0.04SNDK1,523 mentions▲ +0.11SPCX1,495 mentions▲ +0.08NBIS1,421 mentions▲ +0.09HTZ1,232 mentions▲ +0.10NVDA1,190 mentions▲ +0.08META1,018 mentions▲ +0.03MSFT841 mentions▲ +0.06

Equity · Healthcare

JBIO

Jade Biosciences, Inc. · NasdaqCM

$21 +2.56% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 40 sessions
$25 $10 20 May 17 Jul

The line runs $23.27 on 20 May through $21 on 17 July, on a scale from $10 to $25. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of JBIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $23.27 on 20 May 2026 through $21 on 17 July 2026.

Market cap $1.3B
52-week range $6.85 – $26.83
Avg volume 293.9K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

JBIO insider trades

SEC Form 4

JBIO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 6 October 2025.

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
06 Oct 2025 Fairmount Funds Management LLC Award 2,188,173 $20.00M
14 Jul 2025 Dahms Bradford D. Chief Financial Officer Award 526,000

JBIO reported financials

SEC EDGAR XBRL

JBIO reported net income of −$127.4M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$127.4M 31 Dec 2025 fiscal year
Diluted EPS −$3.19 31 Dec 2025 fiscal year
Total assets $472.1M 30 Jun 2026 at period end
Total equity $439.9M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

JBIO earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.76 —
31 Mar 2026 Q1 2026 $-0.57 —
31 Dec 2025 FY 2025 $-3.19 —
30 Sep 2025 Q3 2025 $-0.48 —
30 Jun 2025 Q2 2025 $-0.86 —
31 Mar 2025 Q1 2025 $-12.10 —
31 Dec 2024 FY 2024 $-14.89 —
30 Sep 2024 Q3 2024 $-5.16 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

JBIO institutional holders

SEC Form 13F

11 of the 45 institutional funds we track reported a JBIO position for the quarter ended 30 Jun 2026 — a combined $95.9M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Baker Bros. Advisors Trimmed −25.0% shares 1,230,426 $27.3M
Citadel Advisors Added +577.3% shares 929,407 $20.7M
Balyasny Asset Management Added +118.3% shares 878,726 $19.5M
Marshall Wace Trimmed −38.0% shares 585,761 $13.0M
Millennium Management Added +96.5% shares 314,548 $7.0M
Point72 Asset Management Trimmed −36.7% shares 167,204 $3.7M
Renaissance Technologies Trimmed −45.5% shares 73,591 $1.6M
D. E. Shaw & Co. New position 51,494 $1.1M
Two Sigma Investments Added +148.5% shares 45,361 $1.0M
Man Group New position 26,123 $580K

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

JBIO fails-to-deliver

SEC CNS data

On 16 Jul 2026, 18 shares of JBIO failed to deliver (about $393).

Settlement date Shares failed Notional % of shares out
16 Jul 2026 18 $393 <0.001%
13 Jul 2026 8 $168 <0.001%
08 Jul 2026 710 $16K 0.001%
07 Jul 2026 9 $192 <0.001%
06 Jul 2026 30 $645 <0.001%

Source: SEC fails-to-deliver (CNS) data